[Effect of diethyldithiocarbamate on interleukin 2 production of patients with oral lichen planus and its clinical therapeutic efficacy].
Diethyldithiocarbamate (DTC), a biological augmenting agent specific for T cells, was applied to treat patients with incipient oral lichen planus (OLP) who had been refractory to traditional therapy. DTC was administered orally (5 mg.kg-1, twice a week) for at least 3 months. Interleukin 2 (IL-2) production and lymphocyte proliferation of peripheral blood mononuclear cells (PBMC) were measured before and after the treatment. The bioactivity of IL-2 was determined by the use of IL-2 dependent cell line CTLL-2 and human recombinant IL-2. The results indicated that both IL-2 production of PBMC and lymphocyte proliferation increased (P less than 0.01). Clinical symptoms were improved significantly. The effective rate in 30 patients was 86.7%. It is suggested that the mechanism involves that DTC improves the cellular immunity of the patients.
Su
M
M
Department of Stomatology, Changhai Hospital, Second Military Medical University, China.
Qian
D H
DH
Chen
Y H
YH
D000328:Adult; D000368:Aged; D002455:Cell Division / Q000187:drug effects; D004050:Ditiocarb / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008010:Lichen Planus / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged
D007376:Interleukin-2; D004050:Ditiocarb